BioCryst Pharmaceuticals Inc Files Patent Application for Pyrrolo [1, 2-B] Pyridazine Derivatives as Janus Kinase Inhibitors
New Delhi, Sept. 15 -- USA based BioCryst Pharmaceuticals Inc filed patent application for pyrrolo [1, 2-b] pyridazine derivatives as janus kinase inhibitors. The inventors are Babu Yarlagadda S, Kotian Pravin L, Kumar V Satish, Wu Minwan and Lin Tsu-Hsing.
BioCryst Pharmaceuticals Inc filed the patent application on Feb. 6, 2012. The patent application number is 291/MUMNP/2012 A. The international classification number is C07D 487/04.
According to the Controller General of Patents, Designs & Trade Marks, "The invention provides compounds of formula l: ( I ) or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I."
Does anybody know what this is about? The last sentence "... and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I" is intriguing.
From wikipedia: "Janus kinase inhibitor is a class of medicines that function by inhibiting the effect of one or more of the Janus kinase family of enzymes (JAK1, JAK2, JAK3, TYK2), interfering with the JAK-STAT signaling pathway.
Some JAK2 inhibitors are under development for the treatment of polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Some inhibitors of JAK2 are in clinical trials, e.g. for psoriasis.
JAK3 is also being targeted for a variety of inflammatory diseases, and one has had good results in a phase II trial for rheumatoid arthritis.